298 related articles for article (PubMed ID: 16989288)
1. Abstinence, anticipation, reduction, and treatment (AART): a stepwise approach to the management of atypical antipsychotic side effects.
Kennedy A; Tapp A; Kelly WS; Kilzieh N; Wood AE
Essent Psychopharmacol; 2006; 7(1):1-14. PubMed ID: 16989288
[TBL] [Abstract][Full Text] [Related]
2. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
3. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
Turner MS; Stewart DW
J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
[TBL] [Abstract][Full Text] [Related]
4. The efficacy, safety, and tolerability of antipsychotics in the elderly.
Maixner SM; Mellow AM; Tandon R
J Clin Psychiatry; 1999; 60 Suppl 8():29-41. PubMed ID: 10335669
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.
Keck PE; McElroy SL; Strakowski SM; Soutullo CA
J Clin Psychiatry; 2000; 61 Suppl 4():33-8. PubMed ID: 10739329
[TBL] [Abstract][Full Text] [Related]
6. Switching antipsychotics: an updated review with a focus on quetiapine.
Weiden PJ
J Psychopharmacol; 2006 Jan; 20(1):104-18. PubMed ID: 16204323
[TBL] [Abstract][Full Text] [Related]
7. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.
Meltzer HY; Davidson M; Glassman AH; Vieweg WV
J Clin Psychiatry; 2002; 63 Suppl 9():25-9. PubMed ID: 12088173
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic management of psychosis in the elderly.
Sable JA; Jeste DV
J Nutr Health Aging; 2003; 7(6):421-7. PubMed ID: 14625622
[TBL] [Abstract][Full Text] [Related]
9. Patterns and frequency of atypical antipsychotic prescribing in psychiatric medical centers: a cross-sectional national survey.
Diatta T; Blazejewski S; Portier A; Lignot S; Quesnot A; Moore N; Fourrier-Réglat A
Fundam Clin Pharmacol; 2007 Aug; 21(4):371-8. PubMed ID: 17635175
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic safety and efficacy concerns.
Meyer JM
J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
[TBL] [Abstract][Full Text] [Related]
11. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
Newcomer JW
J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
[TBL] [Abstract][Full Text] [Related]
12. Weight gain--as possible predictor of metabolic syndrome.
Grahovac T; Ružić K; Dadić-Hero E; Sepić-Grahovac D; Sabljić V
Psychiatr Danub; 2011 Mar; 23(1):105-7. PubMed ID: 21448110
[TBL] [Abstract][Full Text] [Related]
13. Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications.
Weiden PJ; Buckley PF
J Clin Psychiatry; 2007; 68 Suppl 6():14-23. PubMed ID: 17650055
[TBL] [Abstract][Full Text] [Related]
14. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics.
Meltzer HY
J Clin Psychiatry; 2001; 62 Suppl 27():35-9; discussion 40-1. PubMed ID: 11806488
[TBL] [Abstract][Full Text] [Related]
15. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
[TBL] [Abstract][Full Text] [Related]
16. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder.
McIntyre RS; Konarski JZ
J Clin Psychiatry; 2005; 66 Suppl 3():28-36. PubMed ID: 15762832
[TBL] [Abstract][Full Text] [Related]
17. Side effects as influencers of treatment outcome.
Sharif Z
J Clin Psychiatry; 2008; 69 Suppl 3():38-43. PubMed ID: 18533761
[TBL] [Abstract][Full Text] [Related]
18. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents.
Correll CU
J Clin Psychiatry; 2008; 69 Suppl 4():26-36. PubMed ID: 18533766
[TBL] [Abstract][Full Text] [Related]
19. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
Miller LJ
Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
[TBL] [Abstract][Full Text] [Related]
20. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
Stahl SM; Mignon L; Meyer JM
Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
